Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection.

Literature DB >> 18332169

Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection.

Lee Ann Campbell¹, Cho-Chou Kuo, Robert J Suchland, David M Rothstein.

Abstract

The efficacy of rifalazil and other benzoxazinorifamycins was tested in a mouse model of lung infection against Chlamydia pneumoniae. Rifalazil and six related new chemical entities all showed efficacy after one dose per day for 3 days at either 3 or 1 mg/kg of body weight.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18332169 PMCID： PMC2346613 DOI： 10.1128/AAC.01567-07

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

Keyword Cloud
References

13 in total

Review 1. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

Authors: S F Dowell; R W Peeling; J Boman; G M Carlone; B S Fields; J Guarner; M R Hammerschlag; L A Jackson; C C Kuo; M Maass; T O Messmer; D F Talkington; M L Tondella; S R Zaki
Journal: Clin Infect Dis Date: 2001-07-20 Impact factor: 9.079

2. Cleavage of the N-linked oligosaccharide from the surfaces of Chlamydia species affects infectivity in the mouse model of lung infection.

Authors: Lee Ann Campbell; Amy Lee; Cho-chou Kuo
Journal: Infect Immun Date: 2006-05 Impact factor: 3.441

Review 3. Development potential of rifalazil and other benzoxazinorifamycins.

Authors: David M Rothstein; Christo Shalish; Christopher K Murphy; Andrew Sternlicht; Lee Ann Campbell
Journal: Expert Opin Investig Drugs Date: 2006-06 Impact factor: 6.206

4. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.

Authors: Robert J Suchland; Agnès Bourillon; Erick Denamur; Walter E Stamm; David M Rothstein
Journal: Antimicrob Agents Chemother Date: 2005-03 Impact factor: 5.191

5. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.

Authors: K Hosoe; T Mae; E Konishi; K Fujii; K Yamashita; T Yamane; T Hidaka; T Ohashi
Journal: Antimicrob Agents Chemother Date: 1996-12 Impact factor: 5.191

6. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

Authors: Patricia M Roblin; Tamara Reznik; Andrei Kutlin; Margaret R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 2003-03 Impact factor: 5.191

Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection.

Review 1. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

2. Cleavage of the N-linked oligosaccharide from the surfaces of Chlamydia species affects infectivity in the mouse model of lung infection.

Review 3. Development potential of rifalazil and other benzoxazinorifamycins.

4. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.

5. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.

6. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

7. Detection of Chlamydia pneumoniae by polymerase chain reaction.

Review 8. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.

9. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp.

10. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648.